To examine the efficacy and safety of add-on ipragliflozin in Japanese patients with type 2 diabetes in the early stage of insulin therapy.
| INTRODUCTION
Basal insulin and premixed insulin represent an effective treatment option for patients with inadequate glycaemic control with oral antidiabetic drugs [1] [2] [3] ; however, some patients are still unable to achieve glycaemic targets for a variety of reasons. 4 Other treatment strategies are then required, such as intensifying the insulin regimen or adding an(other) oral antidiabetic drug; however, patients are often reluctant to intensify their insulin regimen because it is restrictive to their daily life and might cause hypoglycaemia and weight gain. Novel oral antidiabetic agents are therefore required to facilitate further improvement in glycaemic control in patients with type 2 diabetes in the early stages of insulin therapy, defined as patients treated with long-acting, intermediate-acting or premixed insulin.
Ipragliflozin, a selective sodium-glucose co-transporter 2 (SGLT2)
inhibitor, was recently approved in Japan for the treatment of type 2 diabetes as monotherapy or in combination with other oral antidiabetic drugs on the basis of clinical trials performed in Japan. [5] [6] [7] The copyright line for this article was changed on 1 June after original online publication.
Considering the beneficial effects of ipragliflozin on glycaemic control observed in these trials and because of the insulin-independent nature of ipragliflozin action and its low risk of hypoglycaemia, adding ipragliflozin to insulin-treated patients is expected to be efficacious and well tolerated without increasing the risk of hypoglycaemia and weight gain. Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used in Japanese patients, and are frequently administered together with insulin, because this was reported to be an effective combination. 8, 9 It is important, therefore, to determine whether DPP-4 inhibitors affect the efficacy of ipragliflozin in insulin-treated patients.
As part of the clinical development of ipragliflozin, the aim of the present study was to examine the efficacy and safety of administering ipragliflozin compared with placebo over 16 weeks in addition to ongoing insulin therapy in Japanese patients with type 2 diabetes, with or without a DPP-4 inhibitor.
| MATERIALS AND METHODS

| Study design
The present study consisted of a 16-week, randomized, double-blind, 
| Patients
Patients aged ≥20 years diagnosed with type 2 diabetes ≥12 weeks before enrolment were eligible if they had been prescribed a stable dose/regimen of insulin (8-40 units/day) for ≥6 weeks, alone or in combination with other oral antidiabetic drugs, had a glycated haemoglobin level (HbA1c) of ≥7.5% to ≤10.5% (≥58 to ≤91 mmol/mol), a maximum change in HbA1c of 1% (10.9 mmol/mol) during the 4-week screening period, and a body mass index of 20.0-45.0 kg/m 2 .
Patients in the early stage of insulin therapy to support basal insulin secretion were eligible if they were prescribed fixed doses of mixed insulin (providing the rapid-acting or ultra-rapid-acting insulin component was not >30% of the total daily dose), intermediate-acting insulin or long-acting insulin alone. Patients using a DPP-4 inhibitor were eligible if they had been prescribed the same drug at a fixed dose for ≥6 weeks before enrolment and its dose was continued throughout the study. Exclusion criteria are listed in File S1.
| Treatments
After a 4-week screening period, patients entered a 2-week singleblind placebo run-in period, then were randomized to receive 50 mg ipragliflozin or placebo, stratified by DPP-4 inhibitor use. The dose of ipragliflozin remained unchanged throughout the treatment period.
Patients using oral antidiabetic drugs other than DPP-4 inhibitors entered an additional 4-week washout period before screening. The randomization list was prepared by the patient registration centre and patients were allocated to study groups at a 2:1 ratio by the investigator.
To reduce hypoglycaemia risk, patients were instructed to measure their fasting blood glucose (FBG) level using self-monitored blood glucose (SMBG) values every morning and to record whether they felt symptoms associated with hypoglycaemia (values were recorded in patient diaries).
Insulin type was unchanged during the treatment period. The dose of insulin was to continue unchanged during the treatment period, unless dose changes were required for safety reasons. The insulin dose could be reduced at the investigator's discretion if FBG concentrations were <3.89 mmol/L (<70 mg/dL) on two consecutive days and the patient was suspected of having hypoglycaemic symptoms. The insulin dose could be increased if FBG (measured by SMBG) was >11.10 mmol/L (>200 mg/dL) on two consecutive days or if the investigator considered it necessary to increase the insulin dose for safety. The insulin dose could be adjusted by a maximum of four units throughout the study, regardless of the number of dose adjustments. If the insulin dose was changed by >4 units, the patient discontinued the study and was prescribed an appropriate treatment regimen.
The patients' diet and exercise therapies at enrolment were continued unchanged throughout the study. Concomitant use of antidiabetic drugs other than insulin and DPP-4 inhibitors used at enrolment was prohibited. Corticosteroids, immunosuppressants, glucagon and glucose could be administered temporarily, but continuous use of these agents was prohibited. 
| Endpoints and assessments
| Statistical analysis
Efficacy analyses were carried out using the full analysis set, defined as all patients who received at least one dose of the study drug and in whom at least one efficacy variable was measured during the treatment period. Safety analyses were performed using the safety analysis set, defined as all patients who received at least one dose of the study drug during the treatment period. Similar statistical methods were applied to other efficacy endpoints.
Numbers and percentages of patients with TEAEs, serious adverse events, TEAEs leading to permanent discontinuation of the study drug or TEAEs of special interest (TEAEs related to hypoglycaemia, urinary tract infection, genital infection, and effects on body fluid volume and electrolytes) were calculated for each treatment group.
No interim analyses were performed. There were no changes to the statistical analysis plan after unblinding, except for adding the efficacy analysis of C-peptide concentrations.
3 | RESULTS
| Patients
A total of 262 patients were randomized and treated with placebo (n = 87) or ipragliflozin (n = 175; Figure 1 ). Of these, 245 patients (placebo, n = 76; ipragliflozin, n = 169) completed the study. Table 1 shows no significant differences in patient characteristics between the groups.
The mean patient age was 59.2 AE 9.3 years in the placebo group and 58.7 AE 11.1 years in the ipragliflozin group, and 27.6% of patients in the placebo group and 34.5% in the ipragliflozin group were aged ≥65 years. At baseline, HbA1c was 8.62% AE 0.86% (70.8 AE 9.5 mmol/ mol) and 8.67% AE 0.77% (71.2 AE 8.4 mmol/mol) in the placebo and ipragliflozin groups, respectively. Insulin preparation types were as follows: 27.6% of the placebo group and 29.8% of the ipragliflozin group were treated with mixed insulin, 6.9% of the placebo group and 6.5% of the ipragliflozin group were on intermediate-acting insulin, and 65.5%
of the placebo group and 63.7% of the ipragliflozin group were on longacting insulin only (glargine 40.4%, detemir 3.1%, degludec 20.8%).
Approximately 50% of patients in each group were current or former smokers, and just over half currently or formerly consumed alcohol.
| Efficacy
Small changes in HbA1c levels were observed in the placebo group: Table 2 ). Figure 2B shows a decrease in FPG in the ipragliflozin group by week 2, which remained constant until week 16 . Consistent with the changes in HbA1c and FPG, the mean change in glycoalbumin from baseline to end of treatment was greater in the ipragliflozin (−3.60%) than in the placebo (+0.20%) group [adjusted mean difference: −3.84%; 95% CI −4.40, −3.29; p < .001 (Table 2) ]. SMBG was performed at seven time points (before and after each meal and at bedtime) at baseline and at the end of the treatment period. Table 2 shows that ipragliflozin, but not placebo, was associated with significant reductions in SMBG at all time points (p = .001).
The adjusted mean difference (ipragliflozin − placebo) for changes HbA1c, an interaction analysis was performed for HbA1c changes.
Interaction analyses for changes in HbA1c showed a statistically significant interaction for use/non-use of a DPP-4 inhibitor × treatment group (p = .042).
| Metabolic parameters
The reduction in body weight was significantly greater in the ipragliflozin (−1.09 kg) than in the placebo (−0.05 kg) group (adjusted mean difference −1.07 kg; p < .001; Table 2 ). By contrast, the change in waist circumference was not significantly different between the placebo Values are presented as the n (%) or mean AE standard deviation.
BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure. The mean changes in glucagon concentrations from baseline to the end of treatment were not significantly different between the placebo and ipragliflozin groups (Table 2 ). In addition, the glucagon concentrations were not significantly different between baseline and the end of treatment in either group (Table 2) . Glucagon concentrations remained unchanged in the ipragliflozin group in patients with and without the use of a concomitant DPP-4 inhibitor (data not shown). The mean changes in leptin concentrations from baseline to the end of treatment were not significantly different between the placebo and ipragliflozin groups ( Table 2 ).
| Safety
We found that TEAEs ( During the treatment period, serious TEAEs were reported in two patients (2.3%) in the placebo group and two patients (1.1%) in the ipragliflozin group (Table 3) . Two serious TEAEs in the placebo Values are presented as the mean AE standard deviation or adjusted mean difference (95% confidence interval). Where the number of patients differed from the number of patients in the full analysis set, the number is given in parentheses.
AMD, adjusted mean difference (ipragliflozin − placebo); EOT, end of the randomized treatment period; FPG, fasting plasma glucose; SMBG, self-monitored blood glucose.
group were cerebral infarction and coronary arterial stent insertion, in one patient each. Both events led to permanent discontinuation of the study for those patients. Cerebral infarction was classified as severe, and was considered by the investigator to be probably related to the study drug; however, that patient was later shown to be in the placebo group, indicating the cerebral infarction was not related to the study drug. Coronary arterial stent insertion was classified as moderate in severity, but was not considered to be related to the study drug. Serious TEAEs in the ipragliflozin group included cough in one patient, and abnormal hepatic function and hypokalaemia in one patient. These events were classified as mild in severity. Abnormal hepatic function and hypokalaemia were considered to be possibly related to the study drug. Both events were resolved 29 days after onset, and the patient continued the study drug.
Hypoglycaemia-related events were observed in 13 patients (14.9%) in the placebo group and 52 patients (29.7%) in the ipragliflozin group. In the placebo group, there were 36 events of hypoglycaemia, all of which were considered possibly or probably related to the study drug, but the events were mild in severity and were resolved on the day of onset. Hypoglycaemia-related TEAEs in the ipragliflozin group were hypoglycaemia (167 events) and hunger (1 event). All of these events were classified as mild in severity. Except for three events of hypoglycaemia in two patients, all of these events were considered possibly or probably related to the study drug. All of the hypoglycaemia-related TEAEs were resolved without any treatment or by the ingestion of sugary foods. None of these patients discontinued the study.
We also analysed whether occurrence of hypoglycaemia was influenced by concomitant use of DPP-4 inhibitors. Of those not ; however, the A number of studies using animal models showed that SGLT2 inhibition reduces insulin resistance. [12] [13] [14] We found that serum adiponectin levels increased with ipragliflozin treatment, suggesting that SGLT2
inhibition also ameliorates insulin resistance in humans. Further studies, including direct evaluation of insulin sensitivity, are needed to establish the possible effects of ipragliflozin on insulin sensitivity in humans.
We observed a significant reduction in C-peptide concentrations in ipragliflozin-treated patients. This was, however, observed in patients with concomitant use of a DPP-4 inhibitor. Preserving endogenous insulin secretion by adding ipragliflozin to ongoing therapy might be beneficial in terms of β-cell protection. We would expect to see a considerable reduction in the number of β cells in our cohort of patients with a mean HbA1c of~8.6% $ (71 mmol/mol) at baseline because it was previously reported that β-cell area was reduced by~45% in Japanese patients with a mean HbA1c of 7.8%
(62 mmol/mol). 15 Although the incidence of hypoglycaemia was greater in the ipragliflozin group than in the placebo group, none of these events was classified as serious. It was reported that 10 and 20 mg dapagliflozin treatment for 12 weeks in insulin-treated patients caused hypoglycaemia in 29.2% and 25.0% of patients, respectively. 16 Empagliflozin 10 or 25 mg for 18 weeks caused hypoglycaemia in 20% and 28% of patients, respectively. 17 Thus, hypoglycaemic frequency by ipragliflozin (29.1%) was similar to that of other SGLT2 inhibitors.
In the present study, urinary tract infection and genital infection occurred in four (2.3%) and seven (4.0%) patients, respectively, in the ipragliflozin group, and in one (1.1%) and no patients, respectively, in the placebo group. These rates are similar to or lower than those reported in other global clinical trials in which patients were treated with an SGLT2 inhibitor in combination with insulin. [16] [17] [18] There is concern about the risk of ketoacidosis with SGLT2 inhibitors. 19 In the present study, an increase in blood ketone bodies was reported as a TEAE in five patients (2.9%) in the ipragliflozin group and one patient (1.1%) in the placebo group, but none of the patients reported any symptoms of ketoacidosis during the study. We observed slight decreases in eGFR in patients treated with ipragliflozin for 16 weeks. An initial decline in eGFR at 18 weeks by canagliflozin was reported to be partially reversed after 52 weeks. 18 Future studies should carefully follow the long-term changes in renal function in patients treated with SGLT2 inhibitors such as ipragliflozin.
The present study had some limitations. First, none of the patients were using intensive insulin regimens; therefore, we cannot generalize the present results to regimens such as basal-bolus injections. Second, other oral antidiabetic drugs, such as sulphonylureas that could cause hypoglycaemia, were washed out before the initial observation period; therefore, caution is necessary when ipragliflozin is used in patients treated with insulin and sulphonylureas.
In conclusion, ipragliflozin add-on therapy to insulin for 16 weeks significantly decreased HbA1c, FPG and SMBG values. Amelioration of glycaemic control was greater in patients concomitantly treated with a DPP-4 inhibitor. Incidences of other TEAEs were within expected ranges according to previous studies of ipragliflozin as monotherapy or in combination with other oral antidiabetic drugs.
